{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:39:46Z","timestamp":1792813186962,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1139466"],"award-info":[{"award-number":["APP1139466"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jtct.2023.03.025","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T20:30:49Z","timestamp":1679689849000},"page":"454.e1-454.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome"],"prefix":"10.1016","volume":"29","author":[{"given":"Tongted P.","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"North","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun A.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne L.C.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Ivey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushrut S.","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4946-5584","authenticated-orcid":false,"given":"Jacqueline M.L.","family":"Widjaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6196-1476","authenticated-orcid":false,"given":"Michael I.","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen E.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2020-0275","authenticated-orcid":false,"given":"David S.","family":"Kliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9497-0996","authenticated-orcid":false,"given":"David J.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.03.025_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.659595","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia: who, when, and how?","volume":"12","author":"Loke","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2023.03.025_bib0002","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1182\/bloodadvances.2020001904","article-title":"Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation","volume":"4","author":"Grimm","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.03.025_bib0003","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a Center for International Blood and Marrow Transplant Research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.03.025_bib0004","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","article-title":"Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions\u2014a retrospective multicenter analysis from the German Cooperative Transplant Study Group","volume":"21","author":"Schroeder","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.03.025_bib0005","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.2004.05.198","article-title":"Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?","volume":"22","author":"Bader","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.03.025_bib0006","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/sj.bmt.1705582","article-title":"Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia","volume":"39","author":"Huisman","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.03.025_bib0007","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/sj.leu.2403719","article-title":"Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation","volume":"19","author":"Zeiser","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.03.025_bib0008","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41409-022-01579-9","article-title":"Chimerism analysis for clinicians: a review of the literature and worldwide practices","volume":"57","author":"Blouin","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.03.025_bib0009","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3324\/haematol.2009.007765","article-title":"Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation","volume":"94","author":"Bornh\u00e4user","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2023.03.025_bib0010","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00277-013-1961-4","article-title":"Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis","volume":"93","author":"Hoffmann","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2023.03.025_bib0011","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2023.03.025_bib0012","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.03.025_bib0013","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/bmt.2013.2","article-title":"CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT","volume":"48","author":"Rosenow","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.03.025_bib0014","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1038\/sj.leu.2403507","article-title":"Prediction of relapse of acute myeloid leukemia in allogeneic transplant recipients by marrow CD34+ donor cell chimerism analysis","volume":"18","author":"Scheffold","year":"2004","journal-title":"Leukemia"},{"issue":"suppl 2","key":"10.1016\/j.jtct.2023.03.025_bib0015","first-page":"S27","article-title":"Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cells","volume":"81","author":"Thiede","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2023.03.025_bib0016","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.025_bib0017","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised International Prognostic Scoring System for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.025_bib0018","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41409-020-01089-6","article-title":"Important factors in implementation of lineage-specific chimerism analysis for routine use","volume":"56","author":"Das","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.03.025_bib0019","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1182\/blood.V86.4.1261.bloodjournal8641261","article-title":"Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease","volume":"86","author":"Mackinnon","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.025_bib0020","doi-asserted-by":"crossref","unstructured":"Khan RA, Brandenburger K. ROCit: performance assessment of binary classifier with visualization. R package version 2.1.1 2020. Available at https:\/\/cran.r-project.org\/web\/packages\/ROCit\/index.html. Accessed April 19, 2023.","DOI":"10.32614\/CRAN.package.ROCit"},{"key":"10.1016\/j.jtct.2023.03.025_bib0021","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jtct.2023.03.025_bib0022","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/bloodadvances.2021006233","article-title":"Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML","volume":"6","author":"Stasik","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.03.025_bib0023","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.03.025_bib0024","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2013-01-479188","article-title":"Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia","volume":"122","author":"Kr\u00f6nke","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.025_bib0025","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2012-10-461749","article-title":"The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML","volume":"122","author":"Shayegi","year":"2013","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723012022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723012022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:11:07Z","timestamp":1763003467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723012022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2666636723012022"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.03.025","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}